A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO
|
|||||
|
       
  |
 One comment - (Comments are closed)  Finance  biomedical, biotechnology, equity, genomics, investment, IPO, life sciences, pharmaceuticals, preclinical, stem cells, university 
Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling One comment - (Comments are closed) Finance biotechnology, economics, equity, investment, IPO, merger, software, venture capital 
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO One comment - (Comments are closed) Finance biomedical, biotechnology, Canada, clinical trials, Covid-19, equity, FDA, investment, IPO, NIH, pharmaceuticals 
Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week One comment - (Comments are closed) Finance economics, entrepreneurs, equity, investment, IPO, merger, statistics, venture capital
A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock. . . . → Read More: Covid-19 Drug Biotech Raises $300M in IPO Comments are closed Finance biomedical, biotechnology, clinical trials, Covid-19, equity, investment, IPO, licensing, life sciences, pharmaceuticals
A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO Comments are closed Finance biomedical, clinical trials, entrepreneurs, equity, investment, IPO, life sciences, pharmaceuticals, psychiatric, U.K.
A three year-old company developing protein-targeted cancer therapies with computational techniques is raising $400 million in its initial public offering of common stock. . . . → Read More: Cancer Protein Therapy Biotech Raises $400M in IPO Comments are closed Finance biomedical, biotechnology, cancer, entrepreneurs, equity, investment, IPO, life sciences, mathematics, pharmaceuticals, physical sciences, university
A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO Comments are closed Finance biomedical, chemistry, clinical trials, equity, investment, IPO, Japan, life sciences, medical device, pharmaceuticals, physical sciences
Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs Comments are closed Finance biomedical, biotechnology, clinical trials, entrepreneurs, equity, genomics, investment, IPO, life sciences, mathematics, medical device, pharmaceuticals, physical sciences
A biotechnology company developing treatments for disease and enhanced agricultural products with genome editing is raising $126 million in its initial public offering, or IPO, of common stock. . . . → Read More: Genome Editing Biotech Raises $126M in IPO Comments are closed Finance agriculture, biomedical, biotechnology, cancer, equity, genomics, investment, IPO, life sciences, pharmaceuticals |
||||
|
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||